ライフサイエンスコーパス: arginine vasopressin

1 with placebo was 54 +/- 4 mins (p < .05 vs. arginine vasopressin).

2 dipsia with the use of dDAVP (1-desamino-8-D-arginine-vasopressin).

3 d to monitor real-time exocytosis induced by arginine vasopressin.

4 V(2)-antagonist d(CH(2))(5)[D-Ile(2), Ile(4)]arginine vasopressin.

5 d affiliative behaviour after injection with arginine vasopressin.

6 uding thapsigargin, ionomycin, caffeine, and arginine vasopressin.

7 The immature kidney is resistant to arginine vasopressin.

8 mulation of the renin-aldosterone system and arginine vasopressin.

9 receptors for gastrin-releasing peptide and arginine vasopressin.

10 ized following stimulation with the agonist, arginine-vasopressin.

11 ton smoke), or an injured group treated with arginine vasopressin (0.02 IU.min(1)) from 1 hr after in

12 Arginine vasopressin (0.1 and 1.0 nM), endothelin-1 (10

13 urvivors (n = 10) received a bolus of either arginine vasopressin (0.2 units/kg) or placebo during th

14 itated over 60 mins with saline (8.5 mL/kg), arginine vasopressin (0.4 IU/kg bolus plus 0.08 IU x kg

15 ists thrombin 0.1 U/mL, ADP 10(-6) mol/L, or arginine vasopressin 10(7) mol/L; and studied for Ca2+ m

16 Arginine vasopressin (100 and 500 pm) and the PKC activa

17 e effects of intranasal administration of an arginine vasopressin 1A and 1B receptor agonist against

18 (-1)) or continuous intravenous infusions of arginine vasopressin (3 pmol.kg(-1).min(-1)), the select

19 1-Deamino-8-D-arginine vasopressin (a V2 receptor agonist, 0.1 nM) sim

20 amethylenepropionic acid),2-0-methyltyrosine]arginine vasopressin, a selective V1a vasopressin antago

21 The patch-clamp technique was used to record arginine vasopressin activation of nonselective cation c

22 in was measured immediately before exogenous arginine vasopressin administration in 10 patients; only

23 After 1-desamino-8-d-arginine-vasopressin administration or water deprivation

24 for melanin concentrating hormone, oxytocin, arginine vasopressin, agouti-related protein and alpha-m

25 opment and activity of anterior hypothalamic arginine vasopressin (AH-AVP).

26 costerone and the vasotocin receptor agonist arginine vasopressin, alone and in combination, on the s

27 Arginine vasopressin also may directly and adversely aff

28 urine after the treatment of desamino-cis, D-arginine vasopressin, an antidiuretic hormone.

29 to test the memory-enhancing effects of the arginine vasopressin analog [pGlu4, Cyt6] AVP (4-8) at a

30 fluid accumulation was partially reduced by arginine vasopressin and almost completely blocked by se

31 isual sources and contains neurons producing arginine vasopressin and calretinin.

32 tightly controlled by the pituitary hormone arginine vasopressin and defective trafficking results i

33 In the laboratory, pairing is regulated by arginine vasopressin and its predominant CNS receptor, v

34 ave determined the structure and function of arginine vasopressin and its receptors, the role of the

35 Arginine vasopressin and norepinephrine are equally effe

36 e action potential E-wave and the release of arginine vasopressin and oxytocin (S-wave).

37 r-mediated von Willebrand factor increase by arginine vasopressin and the potential benefit of select

38 illing induces the nonosmotic stimulation of arginine vasopressin and upregulation of aquaporin 2 fol

39 containing two peptides found in SCN cells, arginine vasopressin and vasoactive intestinal polypepti

40 -adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic pept

41 and release corticotropin-releasing hormone, arginine vasopressin, and other secretagogues, are respo

42 In contrast, pressor hormones like arginine-vasopressin, angiotensin II, and endothelin bin

43 Expression of oxytocin, oxytocin receptor, arginine vasopressin, arginine vasopressin V1a receptors

44 leasing factor (CRF) (0.5 microg kg(1)) plus arginine vasopressin (AVP) (0.1 microg kg(1)).

45 dies in several species of rodents show that arginine vasopressin (AVP) acting through a V1A receptor

46 Defining how arginine vasopressin (AVP) acts centrally to regulate ho

47 Arginine vasopressin (AVP) acts synergistically with cor

48 Arginine vasopressin (AVP) affects kidney function via v

49 rs tonically inhibit the secretion of renin, arginine vasopressin (AVP) and adrenocorticotropic hormo

50 PVN) corticotrophin releasing hormone (CRH), arginine vasopressin (AVP) and anterior pituitary proopi

51 study was undertaken to define the impact of arginine vasopressin (AVP) and atrial natriuretic peptid

52 In addition, plasma arginine vasopressin (AVP) and atrial natriuretic peptid

53 partial colocalization with the neuropeptide arginine vasopressin (AVP) and clock proteins (PER2 and

54 rotransmitter function for the neuropeptides arginine vasopressin (AVP) and corticotropin releasing f

55 role for VIP augmented by contributions from arginine vasopressin (AVP) and gastrin-releasing peptide

56 tated urea transport is regulated acutely by arginine vasopressin (AVP) and hyperosmolality in rat te

57 lar response to the neurohypophyseal hormone arginine vasopressin (AVP) and in the expression of oxid

58 lationship between cerebrospinal fluid (CSF) arginine vasopressin (AVP) and indices of aggression and

59 The neuropeptides arginine vasopressin (AVP) and oxytocin (OT) are key mod

60 Arginine vasopressin (AVP) and oxytocin (OT) influence s

61 voltage-gated Ca(2+) channel currents and on arginine vasopressin (AVP) and oxytocin (OT) release fro

62 m (CNS) terminals contribute functionally to arginine vasopressin (AVP) and oxytocin (OT) secretion.

63 pophysial nerve terminals, the neurohormones arginine vasopressin (aVP) and oxytocin (OT) undergo Ca(

64 Arginine vasopressin (AVP) and related peptides affect s

65 e paraventricular nucleus (PVN) that release arginine vasopressin (AVP) and specifically, that increa

66 o examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure.

67 Circulating levels of arginine vasopressin (AVP) are elevated during hypovolem

68 Corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) are pivotal mediators of the

69 o (BB) rat with CDI, the mRNA and protein of arginine vasopressin (AVP) are present in the hypothalam

70 Oxytocin (OT) and arginine vasopressin (AVP) are two small, related neurop

71 This was dependent on the neuropeptide arginine vasopressin (AVP) because it was prevented by p

72 oro rats were treated with a 5-d infusion of arginine vasopressin (AVP) by osmotic minipump, the 117-

73 f corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) cause a depolarization of cor

74 r characterized by post-natal development of arginine vasopressin (AVP) deficiency due to mutations i

75 ne vasotocin (AVT) and its mammalian homolog arginine vasopressin (AVP) demonstrate several relations

76 Arginine vasopressin (AVP) enhances water reabsorption i

77 In A7r5 cells, arginine vasopressin (AVP) evoked a striking Ca(2+) entr

78 Secretion of the neuropeptide arginine vasopressin (AVP) from the neurohypophysis is o

79 Mutations in the arginine vasopressin (AVP) gene cause autosomal dominant

80 etes insipidus is caused by mutations in the arginine vasopressin (AVP) gene.

81 Arginine vasopressin (AVP) has a key role in osmoregulat

82 Recently, the mammalian neuropeptide arginine vasopressin (AVP) has been implicated in aggres

83 on corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) heteronuclear RNA (hnRNA) exp

84 more subtle, although reliable, increase in arginine vasopressin (AVP) hnRNA in this same compartmen

85 The role of arginine vasopressin (AVP) in the nongenomic transfer of

86 e interaction of 5-HT receptor agonists with arginine vasopressin (AVP) in the regulation of offensiv

87 er2, and mCry1 and the clock-controlled gene arginine vasopressin (AVP) in the SCN.

88 e, the synthesis of the antidiuretic hormone arginine vasopressin (AVP) increases in the hypothalamus

89 Exposure of vascular smooth muscle cells to arginine vasopressin (AVP) increases smooth muscle alpha

90 There is ample evidence that arginine vasopressin (AVP) is a component of the neuroho

91 Arginine vasopressin (AVP) is a neurohypophysial hormone

92 Arginine vasopressin (AVP) is a vasoactive hormone that

93 ues corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) is not clear.

94 Arginine vasopressin (AVP) is often expressed in small c

95 Arginine vasopressin (AVP) is present in both magnocellu

96 Arginine vasopressin (AVP) levels are elevated in propor

97 ability accompanied by elevated circulating arginine vasopressin (AVP) levels in SHR-A3 compared wit

98 presence of SIADH, yet who had undetectable arginine vasopressin (AVP) levels.

99 c corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) messenger and heteronuclear R

100 vasotocin (AVT) and its mammalian homologue arginine vasopressin (AVP) modulate reproduction-related

101 The neuropeptide arginine vasopressin (AVP) modulates a variety of specie

102 ify corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mRNA expression in the brain.

103 in-releasing hormone (CRH) and parvocellular arginine vasopressin (AVP) mRNA expression relative to s

104 Corticotropin releasing factor (CRF) and arginine vasopressin (AVP) mRNA levels were analyzed by

105 of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mRNAs in the paraventricular

106 of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) mRNAs, the primary hypothalam

107 related with the enhanced development of the arginine vasopressin (AVP) neural system and reduced dev

108 on of the pituitary, which contains axons of arginine vasopressin (AVP) neurons from the hypothalamic

109 ic cells of the SCN, including VIP, GRP, and arginine vasopressin (AVP) neurons, with each ipRGC inne

110 of centrally administered oxytocin (OT) and arginine vasopressin (AVP) on partner preference formati

111 e PVT-projecting SCN cells containing either arginine vasopressin (AVP) or gastrin releasing peptide

112 nd revealed circadian neurons that contained arginine vasopressin (AVP) or vasoactive intestinal poly

113 In Syrian hamsters, arginine vasopressin (AVP) plays a critical role in the

114 dominant disorder caused by mutations in the arginine vasopressin (AVP) precursor.

115 rder caused by a variety of mutations in the arginine vasopressin (AVP) precursor.

116 oping hyponatremia from numerous stimuli for arginine vasopressin (AVP) production, such as volume de

117 Synthetic arginine vasopressin (AVP) receptor agonists able to ind

118 Arginine vasopressin (AVP) regulates fluid balance and b

119 Arginine vasopressin (AVP) regulates the osmotic water p

120 ogen lowers the plasma osmotic threshold for arginine vasopressin (AVP) release but without commensur

121 rdinates autonomic responses in part through arginine vasopressin (AVP) released in medial nucleus tr

122 Arginine vasopressin (AVP) represents a potentially attr

123 Glucopenia stimulates neurohypophyseal arginine vasopressin (AVP) secretion and expression of t

124 duce a parallel increase in water intake and arginine vasopressin (AVP) secretion to promote fluid ex

125 ted adrenocorticotropin (ACTH), cortisol and arginine vasopressin (AVP) secretion, responses that wer

126 Arginine vasopressin (AVP) stimulates the release of ent

127 rincipal cells of the renal collecting duct, arginine vasopressin (AVP) stimulates the synthesis of c

128 , corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adr

129 , corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) to control the release of adr

130 Deficiency of the antidiuretic hormone arginine vasopressin (AVP) underlies diabetes insipidus,

131 eported d[Cha(4)]AVP were evaluated on human arginine vasopressin (AVP) V(1a), V(1b), and V(2) recept

132 blocking agent hexamethonium (5 mg/kg) or an arginine vasopressin (AVP) V1 receptor antagonist (AVPX,

133 astrated males injected centrally with mixed arginine vasopressin (AVP) V1a/b receptor antagonists da

134 Arginine vasopressin (AVP) V2 receptor antagonists inhib

135 d or decreased in these mice, whereas plasma arginine vasopressin (AVP) was increased, supporting a r

136 d doses of phenylephrine, angiotensin II and arginine vasopressin (AVP) were determined at 124 +/- 1

137 ling reveal three distinct binding sites for arginine vasopressin (AVP) within its V2 -receptor (V2 R

138 d/or ACTH secretagogues other than CRF (e.g. arginine vasopressin (AVP)), mediate ACTH stimulation by

139 Here we show that arginine vasopressin (AVP), a neuropeptide that mediates

140 of serum osmolality and serum sodium, plasma arginine vasopressin (AVP), and plasma copeptin concentr

141 he SCN shell contain GABA, calbindin (CALB), arginine vasopressin (AVP), angiotensin II (AII) and met

142 eptide neuromedin U (NMU), or are related to arginine vasopressin (AVP), both of which have PRXa moti

143 er 1-day hypothermia during the perfusion of arginine vasopressin (AVP), D-arginine (D-ARG), L-argini

144 withdrawal increases oxytocin (OT), but not arginine vasopressin (AVP), messenger ribonucleic acid (

145 Arginine vasopressin (AVP), or antidiuretic hormone, is

146 anglia with forskolin, isoproterenol (IPNE), arginine vasopressin (AVP), or papaverine, all of which

147 vasoactive intestinal polypeptide (VIP) and arginine vasopressin (AVP), using in situ hybridization.

148 Renal water reabsorption is controlled by arginine vasopressin (AVP), which binds to V2 receptors,

149 inal peptide (VIP)-expressing cells, but not arginine vasopressin (AVP)-expressing cells, exhibited s

150 able experimental results that indicate that arginine vasopressin (AVP)-independent factors are invol

151 a (or both) were the enzymes responsible for arginine vasopressin (AVP)-induced AA release from A-10

152 Catalase substantially attenuated arginine vasopressin (AVP)-induced Ca(2+) entry in cells

153 Because cAMP is a central modulator of arginine vasopressin (AVP)-induced water transport in th

154 calcium-independent phospholipase A2 during arginine vasopressin (AVP)-mediated mobilization of arac

155 ocalized on the plasma membrane and mediates arginine vasopressin (AVP)-stimulated cAMP accumulation,

156 A V2R, as was the concentration response for arginine vasopressin (AVP)-stimulated cAMP accumulation.

157 In terminal IMCDs, arginine vasopressin (AVP)-stimulated osmotic water perm

158 smooth muscle cells and blocks induction by arginine vasopressin (AVP).

159 93 cells was phosphorylated after binding to arginine vasopressin (AVP).

160 sphorylated following the addition of 100 nM arginine vasopressin (AVP).

161 sis and release of the neuropeptide hormone, arginine vasopressin (AVP).

162 examined the responsiveness of the kidney to arginine vasopressin (AVP).

163 Here, we report that serotonin (5-HT) and arginine-vasopressin (AVP) act in opposite ways in the h

164 In vascular smooth muscle cells, arginine-vasopressin (AVP) activated non-selective catio

165 he context of differences among the lines in arginine-vasopressin (AVP) and light-induced Fos express

166 nonpaternal voles (microtus) have different arginine-vasopressin (AVP) and oxytocin (OT) receptor pa

167 The distribution of arginine-vasopressin (AVP) cells in the SCN overlapped w

168 e control animals despite comparable urinary arginine-vasopressin (AVP) excretion in the two groups.

169 Our experience in adults prompted the use of arginine-vasopressin (AVP) in a similar group of critica

170 onatremic patients have elevated circulating arginine-vasopressin (AVP) levels, we examined whether A

171 suprachiasmatic nucleus output neuropeptide arginine-vasopressin (AVP) on the activity of preoptic a

172 olvement of different groups of hypothalamic arginine-vasopressin (AVP) synthesizing neurons in multi

173 In golden hamsters, microinjections of arginine-vasopressin (AVP) within the anterior hypothala

174 ization of Fos expression and oxytocin (OT), arginine-vasopressin (AVP), corticotrophin-releasing fac

175 tances corticotropin-releasing factor (CRF), arginine-vasopressin (AVP), histidine decarboxylase (HDC

176 owed by an antibody to either oxytocin (OT), arginine-vasopressin (AVP), or corticotropin releasing h

177 Levels of hypophysial portal arginine-vasopressin (AVP), plasma ACTH and plasma corti

178 We evaluated contraction (KCl and arginine vasopressin [AVP]) and dilation (acetylcholine

179 for MT, OT, and the mammalian AVT homologue, arginine vasopressin [AVP]).

180 1a receptor/vasopressin V2 receptor agonist arginine vasopressin because of its lack of agonist acti

181 Patients with plasma arginine vasopressin below the lower quartile (< 9.2 pg/

182 B, neurotensin, gastrin, cholecystokinin and arginine vasopressin bind seven transmembrane-spanning r

183 is is the first study that demonstrates that arginine vasopressin boosts placebo effects and that the

184 esent study, we have used an Ad encoding the arginine vasopressin cDNA (AdAVP) in an AVP-deficient an

185 Arginine vasopressin colocalized with EGFP more often in

186 ynamic instability and relatively low plasma arginine vasopressin concentration (< 9.2 pg/mL) had not

187 ildren undergoing open heart surgery, plasma arginine vasopressin concentration is relatively low at

188 rebral magnetic resonance imaging, and serum arginine vasopressin concentration) were compatible with

189 iopulmonary bypass for measurement of plasma arginine vasopressin concentration.

190 in, melanin-concentrating hormone, oxytocin, arginine vasopressin, corticotropin-releasing hormone (C

191 The glutamine(4) residue in [deamino-Cys(1)]arginine vasopressin (dAVP) was replaced by a broad seri

192 Administration of 1-desamino-8-D-arginine vasopressin (DDAVP) causes a rapid, concomitant

193 In response to 1-desamino-8-D-arginine vasopressin (DDAVP), peak VWF:Ag levels exceede

194 ximum antidiuresis produced by 1-deamino-8-D-arginine vasopressin (DDAVP).

195 Infusion of 1-deamino-(8-D-arginine)-vasopressin (dDAVP), a vasopressin V2 receptor

196 Administration of 1-desamino-8-D-arginine-vasopressin (DDAVP) to patients with type 1 von

197 After 4-d pretreatment with 1-deamino-[8-D-arginine]-vasopressin (dDAVP) by osmotic mini-pump, rats

198 he first study, two groups of 1-deamino-[8-D-arginine]-vasopressin (dDAVP)-infused rats were water-lo

199 Desmopressin (1-deamino-8-d-arginine vasopressin [DDAVP]) releases stored VWF and FV

200 ins (Saccharomyces cerevisiae) that required arginine vasopressin-dependent receptor/G protein coupli

201 termine whether deletion of GSK3beta affects arginine vasopressin-dependent renal water reabsorption.

202 1-deamino-8-d-arginine vasopressin (desmopressin [DDAVP]) is clinicall

203 se to locally applied phenylephrine, Ang II, arginine vasopressin, elevated [K(+)]o and acetylcholine

204 ses of the basilar artery to angiotensin II, arginine vasopressin, endothelin-1 and U-46619.

205 kg i.p.) rats in response to angiotensin II, arginine vasopressin, endothelin-1, and the thromboxane

206 is strongly stimulated immediately following arginine-vasopressin exposure of H9c2 ventricular myocyt

207 Arginine vasopressin fell from 5.0 +/- 4.8 fmol/mL at ba

208 With arginine vasopressin, five of five animals survived 300

209 riptional regulation of the clock-controlled arginine vasopressin gene in the suprachiasmatic nuclei

210 ucleotide deletion in the second exon of the arginine vasopressin gene, resulting in the synthesis of

211 Hb ratio was lower in the FE 202158 than the arginine vasopressin group (p < .005).

212 n the desmopressin (40 +/- 6%, p < .001) and arginine vasopressin groups (25 +/- 4%, p < .001).

213 Arginine vasopressin has been implicated in the renal wa

214 t the SCN, including a limited population of arginine vasopressin-immunoreactive (AVP-IR) neurons.

215 ents were designed to evaluate whether early arginine vasopressin improves acute outcome following re

216 Mean plasma arginine vasopressin in group B was 104 +/- 160 at 4 hrs

217 d by the V2 receptor agonist (1-desamino-8-D-arginine vasopressin) in wild-type mice, is lacking in k

218 The V2 receptor agonist 1-deamino-8-d-arginine vasopressin increased renal cAMP and recovered

219 Here we show that centrally administered arginine vasopressin increases affiliative behaviour in

220 was no increase in either angiotensin II- or arginine vasopressin-induced inositol phosphate formatio

221 Arginine vasopressin influences male reproductive and so

222 Compared with controls, arginine vasopressin infusion improved myocardial functi

223 ular functions and tissue oxygenation, while arginine vasopressin infusion may only improve blood pre

224 However, with phenylephrine vs. arginine vasopressin, intracranial pressure averaged >10

225 os-IR within the SCN overlapped with that of arginine-vasopressin-IR (AVP-IR) and vasoactive intestin

226 We tested the hypothesis that arginine vasopressin is a suitable alternative to norepi

227 l and the secretion of antidiuretic hormone (arginine vasopressin) is fully suppressed, the human kid

228 Although the native hormone arginine-vasopressin leads to activation of both the sti

229 Arginine vasopressin levels are elevated in infants and

230 tent, lactate, pH, standard base excess, and arginine vasopressin levels were determined, and systemi

231 In addition, we found a gene encoding an arginine-vasopressin-like (AVPL) peptide and one for its

232 or all known insect neuropeptides except for arginine-vasopressin-like peptide (AVLP), CNMamide, neur

233 The peptide arginine-vasopressin (mammals) and its evolutionary prec

234 Arginine vasopressin may contribute to abnormalities in

235 a ryanodine receptor antagonist, blocked the arginine vasopressin-mediated increase in P(f) and block

236 Arginine vasopressin modulates a number of species-typic

237 sed the corticotrophin-releasing hormone and arginine vasopressin mRNA as well as the corticosterone

238 In contrast, arginine vasopressin mRNA was detected in only five of t

239 y 300 mins after traumatic brain injury with arginine vasopressin (n = 8) vs. placebo (n = 8), the fl

240 ally unchanged from its baseline mean plasma arginine vasopressin of 5.0 +/- 10.4 (p = .977).

241 Mean plasma arginine vasopressin of group A was also significantly l

242 ection of neurogenic hypotension with either arginine vasopressin or norepinephrine limits edema, red

243 otropin-releasing hormone and do not express arginine vasopressin or oxytocin.

244 neurons within the PVN also contained either arginine vasopressin or oxytocin.

245 blood with either 0.1 unit x kg(-1) x hr(-1) arginine vasopressin or placebo was titrated to a mean a

246 vel, an additional continuous IV infusion of arginine vasopressin or selepressin was titrated to rais

247 d detectable amounts of the radioligand, [3H]arginine vasopressin, or to activate the G(S)/adenylyl c

248 fails to secrete neuropeptides somatostatin, arginine vasopressin, oxytocin, corticotropin-releasing

249 sexual antagonism acting on loci within the arginine vasopressin-oxytocin pathway explains how genet

250 Plasma arginine vasopressin (pAVP), which is inhibited by psych

251 Mean plasma arginine vasopressin (pg/mL) for all patients was 21 +/-

252 Copeptin is a stable arginine vasopressin precursor associated with increased

253 sponsible for the clearance of misfolded pro-arginine vasopressin (proAVP) in the ER.

254 of corticotropin, norepinephrine, cortisol, arginine vasopressin, prolactin, corticotropin-releasing

255 Early supplemental arginine vasopressin rapidly corrected cerebral perfusio

256 The V1a arginine vasopressin receptor (V1aR) expressed in HEK 29

257 Expression of arginine vasopressin receptor 1a (Avpr1a) and oxytocin r

258 ts of a single 20 mg intravenous dose of the arginine vasopressin receptor 1A (V1a) antagonist, RG771

259 ndem repeats RS1, RS3 and AVR in the AVPR1A (arginine vasopressin receptor 1a) gene and STin2 in the

260 8396 single-nucleotide polymorphism near the arginine vasopressin receptor 1b gene is associated with

261 396 single-nucleotide polymorphism (near the arginine vasopressin receptor 1b gene) was significantly

262 urine concentration mechanism by modulating arginine vasopressin receptor 2 and AQP2 expression in t

263 east in part, to decreased expression of the arginine vasopressin receptor 2 in ptip mutants.

264 reproprotein, the oxytocin receptor, and the arginine vasopressin receptor contain VDREs for activati

265 and excellent selectivity against the human arginine vasopressin receptors.

266 Low-dose arginine vasopressin reduced nitrosative stress and impr

267 mic function and tissue oxygenation, whereas arginine vasopressin resuscitation improves blood pressu

268 arance without a concomitant increase in the arginine vasopressin serum levels.

269 groups without a concomitant increase in the arginine vasopressin serum levels.

270 likely the optimal candidates for exogenous arginine vasopressin should hemodynamic compromise occur

271 Here, we show that arginine vasopressin specifically activates interneurons

272 Upon arginine vasopressin stimulation, this chimeric receptor

273 receptor/vasopressin type 2 receptor agonist arginine vasopressin, the selective vasopressin type 1a

274 clude corticotropin-releasing hormone (CRH); arginine vasopressin; the proopiomelanocortin-derived pe

275 i, human adipocytes were treated with KCl or arginine vasopressin to stimulate voltage- and receptor-

276 -24 hrs; p </= .001 each) were attenuated in arginine vasopressin-treated animals compared with contr

277 I and muscle perfusion by 42% and 51%, while arginine vasopressin treatment reduced heart rate by 31%

278 ased fluid accumulation to levels similar to arginine vasopressin treatment.

279 AVP activates arginine vasopressin type 1A (V(1A))/Galpha(q)-coupled r

280 The arginine-vasopressin type 2 receptor (V2R), a prototypic

281 s of fluorescent benzazepine ligands for the arginine-vasopressin V(2) receptor (AVP V(2)R) was synth

282 rons project from the PVN to the RVLM and if arginine vasopressin (V(1A)) receptor expression increas

283 least in part, by changes in the density of arginine vasopressin-V(1a) receptors (V(1a)R).

284 ion of a ganglion blocking agent, but not an arginine vasopressin V1 receptor antagonist, lowered blo

285 The arginine vasopressin V1a receptor gene (AVPR1A) has been

286 in, oxytocin receptor, arginine vasopressin, arginine vasopressin V1a receptors, and corticotrophin-r

287 The arginine vasopressin/vasotocin (AVP/AVT) system is stron

288 In many vertebrates, the arginine vasopressin (VP) innervation of the forebrain,

289 In series 2, with arginine vasopressin vs. placebo, cerebral perfusion pre

290 Mean plasma arginine vasopressin was 4.9 +/- 2.6 in group A at 4 hrs

291 Arginine vasopressin was as effective as phenylephrine f

292 The hypothesis was that arginine vasopressin was as effective as phenylephrine f

293 Plasma arginine vasopressin was measured immediately before exo

294 ion of femoral arterial rings in response to arginine vasopressin was significantly enhanced in both

295 After 120 mins, phenylephrine or arginine vasopressin was titrated to cerebral perfusion

296 lality after administration of 1-deamino-8-D-arginine-vasopressin was approximately 700 mosm/kg H(2)O

297 Plasma renin activity, aldosterone and arginine vasopressin were also significantly decreased i

298 s doses of phenylephrine, angiotensin II and arginine vasopressin were recorded.

299 Conversely, responses to KCl or arginine vasopressin were unaffected.

300 However, the 24 hr rhythms of arginine vasopressin within the SCN and plasma corticost